Literature DB >> 11920585

CD70/CD27 ligand, a member of the TNF family, is expressed in human brain tumors.

Janka Held-Feindt1, Rolf Mentlein.   

Abstract

CD70 (CD27 ligand) has been implicated in proapoptotic signals mediated by its receptor CD27 in lymphocytes as well as in proliferative effects induced by reverse signaling in CD70-positive hematopoetic tumor cells. We were able to show that CD70 is expressed at the mRNA and protein level in human meningioma cells, glioma cells from solid human gliomas as well as glioma cell lines and 1 ependynoma. The intensity of CD70 expression varies considerably between different samples from 1 tumor type. In the U343 glioma cell line, CD70 was preferentially localized in the cell processes. Thus, our studies identify CD70 as a new marker molecule in brain tumors that are of nonhematopoetic origin. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11920585     DOI: 10.1002/ijc.10207

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

Review 1.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

Review 2.  CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?

Authors:  Brooke L Prinzing; Stephen M Gottschalk; Giedre Krenciute
Journal:  Expert Rev Anticancer Ther       Date:  2018-03-16       Impact factor: 4.512

3.  Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma.

Authors:  Drew Pratt; Stefania Pittaluga; Maryknoll Palisoc; Patricia Fetsch; Liqiang Xi; Mark Raffeld; Mark R Gilbert; Martha Quezado
Journal:  J Neuropathol Exp Neurol       Date:  2017-08-01       Impact factor: 3.685

4.  CD70, a novel target of CAR T-cell therapy for gliomas.

Authors:  Linchun Jin; Haitao Ge; Yu Long; Changlin Yang; Yifan Emily Chang; Luyan Mu; Elias J Sayour; Gabriel De Leon; Qiong J Wang; James C Yang; Paul S Kubilis; Hongbo Bao; Songsong Xia; Dunyue Lu; Yingjun Kong; Li Hu; Yujiao Shang; Chencheng Jiang; Jing Nie; Shimin Li; Yunhe Gu; Jiahang Sun; Duane A Mitchell; Zhiguo Lin; Jianping Huang
Journal:  Neuro Oncol       Date:  2018-01-10       Impact factor: 12.300

5.  Deficiency of the protein-tyrosine phosphatase DEP-1/PTPRJ promotes matrix metalloproteinase-9 expression in meningioma cells.

Authors:  Astrid Petermann; Yvonn Stampnik; Yan Cui; Helen Morrison; Doreen Pachow; Nadine Kliese; Christian Mawrin; Frank-D Böhmer
Journal:  J Neurooncol       Date:  2015-02-12       Impact factor: 4.130

Review 6.  Immunotherapeutic approaches for glioma.

Authors:  Hideho Okada; Gary Kohanbash; Xinmei Zhu; Edward R Kastenhuber; Aki Hoji; Ryo Ueda; Mitsugu Fujita
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

Review 7.  The role of tumor necrosis factor receptor superfamily members in mammalian brain development, function and homeostasis.

Authors:  Jason P Twohig; Simone M Cuff; Audrey A Yong; Eddie C Y Wang
Journal:  Rev Neurosci       Date:  2011-08-24       Impact factor: 4.353

8.  Individualized markers optimize class prediction of microarray data.

Authors:  Pavlos Pavlidis; Panayiota Poirazi
Journal:  BMC Bioinformatics       Date:  2006-07-14       Impact factor: 3.169

9.  CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding.

Authors:  P J Adam; J A Terrett; G Steers; L Stockwin; J A Loader; G C Fletcher; L-S Lu; B I Leach; S Mason; A C Stamps; R S Boyd; F Pezzella; K C Gatter; A L Harris
Journal:  Br J Cancer       Date:  2006-08-07       Impact factor: 7.640

10.  CD70-CD27 ligation between neural stem cells and CD4+ T cells induces Fas-FasL-mediated T-cell death.

Authors:  Eun Mi Lee; Sunghoon Hurh; Bumrae Cho; Kook-Hwan Oh; Seung U Kim; Charles D Surh; Jonathan Sprent; Jaeseok Yang; Jae Young Kim; Curie Ahn
Journal:  Stem Cell Res Ther       Date:  2013-05-21       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.